DNA methylation alterations in muscle of critically ill patients.

Critical illness DNA methylation Epigenetics Intensive care unit-acquired muscle weakness Muscle

Journal

Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883

Informations de publication

Date de publication:
06 2022
Historique:
revised: 15 09 2021
received: 28 06 2021
accepted: 21 02 2022
pubmed: 12 3 2022
medline: 11 6 2022
entrez: 11 3 2022
Statut: ppublish

Résumé

Intensive care unit (ICU)-acquired weakness can persist beyond ICU stay and has been associated with long-term functional impairment of ICU survivors. Recently, DNA methylation alterations were found in the blood of ICU patients, partially explaining long-term developmental impairment of critically ill children. As illness-induced aberrant DNA methylation theoretically could also be involved in long-term weakness, we investigated whether the DNA methylation signature in muscle of adult critically ill patients differs from that in muscle of healthy controls. Genome-wide methylation was determined (Infinium® HumanMethylationEPIC BeadChips) in DNA extracted from skeletal muscle biopsies that had been collected on Day 8 ± 1 in ICU from 172 EPaNIC-trial patients [66% male sex, median age 62.7 years, median body mass index (BMI) 25.9 kg/m In DNA from ICU patients, 565 CpG sites, associated with 400 unique genes, were differentially methylated as compared with controls (average difference 3.2 ± 0.1% ranging up to 16.9%, P < 0.00005). Many of the associated genes appeared highly relevant for muscle structure and function/weakness, including genes involved in myogenesis, muscle regeneration, nerve/muscle membrane excitability, muscle denervation/re-innervation, axon guidance/myelination/degeneration/regeneration, synapse function, ion channelling with especially calcium signalling, metabolism (glucose, protein, and fat), insulin signalling, neuroendocrine hormone regulation, mitochondrial function, autophagy, apoptosis, oxidative stress, Wnt signalling, transcription regulation, muscle fat infiltration during regeneration, and fibrosis. In patients as compared with controls, we also identified two hypomethylated regions, spanning 18 and 3 CpG sites in the promoters of the HIC1 and NADK2 genes, respectively (average differences 5.8 ± 0.01% and 12.1 ± 0.04%, family-wise error rate <0.05). HIC1 and NADK2 play important roles in muscle regeneration and postsynaptic acetylcholine receptors and in mitochondrial processes, respectively. Nine of 10 investigated genes containing DNA methylation alterations were differentially expressed in patients as compared with controls (P ≤ 0.03). Critically ill patients present with a different DNA methylation signature in skeletal muscle as compared with healthy controls, which in theory could provide a biological basis for long-term persistence of weakness in ICU survivors. ClinicalTrials.gov: NCT00512122, registered on 31 July 2007.

Sections du résumé

BACKGROUND
Intensive care unit (ICU)-acquired weakness can persist beyond ICU stay and has been associated with long-term functional impairment of ICU survivors. Recently, DNA methylation alterations were found in the blood of ICU patients, partially explaining long-term developmental impairment of critically ill children. As illness-induced aberrant DNA methylation theoretically could also be involved in long-term weakness, we investigated whether the DNA methylation signature in muscle of adult critically ill patients differs from that in muscle of healthy controls.
METHODS
Genome-wide methylation was determined (Infinium® HumanMethylationEPIC BeadChips) in DNA extracted from skeletal muscle biopsies that had been collected on Day 8 ± 1 in ICU from 172 EPaNIC-trial patients [66% male sex, median age 62.7 years, median body mass index (BMI) 25.9 kg/m
RESULTS
In DNA from ICU patients, 565 CpG sites, associated with 400 unique genes, were differentially methylated as compared with controls (average difference 3.2 ± 0.1% ranging up to 16.9%, P < 0.00005). Many of the associated genes appeared highly relevant for muscle structure and function/weakness, including genes involved in myogenesis, muscle regeneration, nerve/muscle membrane excitability, muscle denervation/re-innervation, axon guidance/myelination/degeneration/regeneration, synapse function, ion channelling with especially calcium signalling, metabolism (glucose, protein, and fat), insulin signalling, neuroendocrine hormone regulation, mitochondrial function, autophagy, apoptosis, oxidative stress, Wnt signalling, transcription regulation, muscle fat infiltration during regeneration, and fibrosis. In patients as compared with controls, we also identified two hypomethylated regions, spanning 18 and 3 CpG sites in the promoters of the HIC1 and NADK2 genes, respectively (average differences 5.8 ± 0.01% and 12.1 ± 0.04%, family-wise error rate <0.05). HIC1 and NADK2 play important roles in muscle regeneration and postsynaptic acetylcholine receptors and in mitochondrial processes, respectively. Nine of 10 investigated genes containing DNA methylation alterations were differentially expressed in patients as compared with controls (P ≤ 0.03).
CONCLUSIONS
Critically ill patients present with a different DNA methylation signature in skeletal muscle as compared with healthy controls, which in theory could provide a biological basis for long-term persistence of weakness in ICU survivors.
TRIAL REGISTRATION
ClinicalTrials.gov: NCT00512122, registered on 31 July 2007.

Identifiants

pubmed: 35274472
doi: 10.1002/jcsm.12970
pmc: PMC9178166
doi:

Banques de données

ClinicalTrials.gov
['NCT00512122']

Types de publication

Clinical Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1731-1740

Subventions

Organisme : KU Leuven
ID : METH14/06
Organisme : Fonds Wetenschappelijk Onderzoek
Organisme : European Research Council
ID : AdvG-2017-785809
Pays : International
Organisme : European Research Council
ID : AdvG-2012-321670
Pays : International

Informations de copyright

© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.

Références

Oncogene. 2011 Jul 14;30(28):3105-26
pubmed: 21441951
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):2259-2261
pubmed: 34904399
Nucleic Acids Res. 2019 Jul 2;47(W1):W199-W205
pubmed: 31114916
Diabetologia. 2012 Dec;55(12):3341-9
pubmed: 22961225
Skelet Muscle. 2019 Apr 16;9(1):9
pubmed: 30992050
Pharmacotherapy. 2013 Dec;33(12):1362-8
pubmed: 23864439
J Appl Physiol (1985). 2017 Apr 1;122(4):952-967
pubmed: 28057818
Nat Commun. 2012;3:1248
pubmed: 23212377
Aging Cell. 2016 Aug;15(4):603-16
pubmed: 27102569
Trials. 2011 Jan 24;12:21
pubmed: 21261975
Nat Commun. 2015 Dec 15;6:10145
pubmed: 26666572
Am J Respir Crit Care Med. 2017 Dec 1;196(11):1422-1433
pubmed: 28809518
Annu Rev Nutr. 2007;27:363-88
pubmed: 17465856
Cancer Lett. 2015 May 1;360(2):106-13
pubmed: 25687886
Int J Epidemiol. 2012 Feb;41(1):200-9
pubmed: 22422453
Epigenomics. 2012 Jun;4(3):325-41
pubmed: 22690668
PLoS One. 2008;3(11):e3686
pubmed: 18997871
Intensive Care Med. 2020 Jun;46(6):1184-1193
pubmed: 31970446
J Cell Physiol. 2006 Apr;207(1):1-11
pubmed: 16155926
Physiol Rev. 2015 Jul;95(3):1025-109
pubmed: 26133937
Bioinformatics. 2012 Mar 15;28(6):882-3
pubmed: 22257669
Clin Epigenetics. 2020 Oct 20;12(1):155
pubmed: 33081814
Bioinformatics. 2014 May 15;30(10):1363-9
pubmed: 24478339
Crit Care Med. 2020 Feb;48(2):142-150
pubmed: 31939781
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Diabetes. 2012 Dec;61(12):3322-32
pubmed: 23028138
Biochim Biophys Acta. 2015 Mar;1849(3):309-16
pubmed: 25598319
N Engl J Med. 2014 Apr 24;370(17):1626-35
pubmed: 24758618
JAMA. 2002 Dec 11;288(22):2859-67
pubmed: 12472328
Lancet Respir Med. 2020 Mar;8(3):288-303
pubmed: 32085844
JAMA Intern Med. 2015 Apr;175(4):523-9
pubmed: 25665067
Methods Mol Biol. 2012;863:359-76
pubmed: 22359306
Intensive Care Med. 2020 Apr;46(4):637-653
pubmed: 32076765
Sci Rep. 2016 Jul 14;6:29334
pubmed: 27411715
Crit Care. 2013 Apr 27;17(2):R81
pubmed: 23622086
Thorax. 2019 Nov;74(11):1037-1045
pubmed: 31481633
Nature. 2013 Oct 24;502(7472):489-98
pubmed: 24153302
Aging Cell. 2014 Apr;13(2):360-6
pubmed: 24304487
N Engl J Med. 2011 Apr 7;364(14):1293-304
pubmed: 21470008
J Cell Physiol. 2017 Nov;232(11):2938-2945
pubmed: 28112397
Hum Mol Genet. 2014 Sep 15;23(18):5009-16
pubmed: 24847004
Lancet Respir Med. 2013 Oct;1(8):621-629
pubmed: 24461665
J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1731-1740
pubmed: 35274472
Crit Care Med. 2011 Feb;39(2):371-9
pubmed: 20959786
Thorax. 2015 Mar;70(3):219-28
pubmed: 25516419
Cell Stem Cell. 2019 Dec 5;25(6):797-813.e9
pubmed: 31809738
N Engl J Med. 2011 Aug 11;365(6):506-17
pubmed: 21714640
Cell Rep. 2018 Nov 13;25(7):1856-1871.e6
pubmed: 30428353
Cell Rep. 2013 Jul 11;4(1):189-204
pubmed: 23810552
PLoS One. 2016 Feb 26;11(2):e0150319
pubmed: 26918767
Am J Respir Crit Care Med. 2016 Oct 1;194(7):821-830
pubmed: 27058306
Bioinformatics. 2017 Feb 15;33(4):558-560
pubmed: 28035024

Auteurs

Lisa Van Dyck (L)

Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Fabian Güiza (F)

Clinical Division of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Inge Derese (I)

Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Lies Pauwels (L)

Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Michaël P Casaer (MP)

Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Clinical Division of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Greet Hermans (G)

Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Medical Intensive Care Unit, Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium.

Pieter J Wouters (PJ)

Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Clinical Division of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Greet Van den Berghe (G)

Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Clinical Division of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Ilse Vanhorebeek (I)

Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH